SG11201911937UA - Amorphous and crystalline forms of ido inhibitors - Google Patents

Amorphous and crystalline forms of ido inhibitors

Info

Publication number
SG11201911937UA
SG11201911937UA SG11201911937UA SG11201911937UA SG11201911937UA SG 11201911937U A SG11201911937U A SG 11201911937UA SG 11201911937U A SG11201911937U A SG 11201911937UA SG 11201911937U A SG11201911937U A SG 11201911937UA SG 11201911937U A SG11201911937U A SG 11201911937UA
Authority
SG
Singapore
Prior art keywords
amorphous
crystalline forms
ido inhibitors
ido
inhibitors
Prior art date
Application number
SG11201911937UA
Other languages
English (en)
Inventor
Jay Powers
Hilary Beck
Maksim Osipov
Maureen Reilly
Hunter Shunatona
James Walker
Mikhail Zibinsky
Tamar Rosenbaum
Ian Young
Jennifer Nelson
Petinka Vlahova
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11201911937UA publication Critical patent/SG11201911937UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201911937UA 2017-06-30 2018-06-29 Amorphous and crystalline forms of ido inhibitors SG11201911937UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527855P 2017-06-30 2017-06-30
PCT/US2018/040262 WO2019006283A1 (en) 2017-06-30 2018-06-29 AMORPHOUS AND CRYSTALLINE FORMS OF IDO INHIBITORS

Publications (1)

Publication Number Publication Date
SG11201911937UA true SG11201911937UA (en) 2020-01-30

Family

ID=64742242

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911937UA SG11201911937UA (en) 2017-06-30 2018-06-29 Amorphous and crystalline forms of ido inhibitors

Country Status (12)

Country Link
US (2) US11236049B2 (https=)
EP (1) EP3644993B1 (https=)
JP (1) JP7690284B2 (https=)
KR (1) KR102630575B1 (https=)
CN (1) CN111093651B (https=)
AU (1) AU2018294314B2 (https=)
CA (1) CA3066789A1 (https=)
EA (1) EA202090119A1 (https=)
IL (1) IL271601B2 (https=)
MX (2) MX391848B (https=)
SG (1) SG11201911937UA (https=)
WO (1) WO2019006283A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7315483B2 (ja) * 2017-06-30 2023-07-26 ブリストル－マイヤーズ スクイブ カンパニー 置換キノリニルシクロヘキシルプロパンアミド化合物および改良されたその製造方法
EP4426022A3 (en) * 2017-11-17 2024-11-20 Telefonaktiebolaget LM Ericsson (publ) Signaling ta-offset in nr
CN110357813A (zh) * 2018-04-09 2019-10-22 信达生物制药(苏州)有限公司 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途
WO2020000236A1 (zh) * 2018-06-27 2020-01-02 深圳仁泰医药科技有限公司 (r)-n-(4-氯苯基)-2-(顺-4-(6-氟喹啉-4-基)环己基)丙酰胺的晶型
WO2021050653A1 (en) * 2019-09-11 2021-03-18 Bristol-Myers Squibb Company Pharmaceutical formulations of indoleamine 2, 3-dioxygenase inhibitors
BR112022009944A2 (pt) * 2019-11-26 2022-08-09 Bristol Myers Squibb Co Sais / cocristais de (r)-n-(4-clorofenil)-2-((1s,4s)-4-(6-fluoroquinolin-4-il)ciclo-hexil)propanamida
AR120935A1 (es) * 2020-01-02 2022-03-30 Hutchison Medipharma Ltd Derivados de amida y usos de los mismos

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US8450351B2 (en) 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036642A2 (en) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
WO2009156652A1 (fr) 2008-05-29 2009-12-30 Saint-Gobain Centre De Recherches Et D'etudes Europeen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
NO2694640T3 (https=) 2011-04-15 2018-03-17
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
JP7315483B2 (ja) 2017-06-30 2023-07-26 ブリストル－マイヤーズ スクイブ カンパニー 置換キノリニルシクロヘキシルプロパンアミド化合物および改良されたその製造方法

Also Published As

Publication number Publication date
CA3066789A1 (en) 2019-01-03
IL271601B1 (en) 2024-01-01
IL271601B2 (en) 2024-05-01
CN111093651A (zh) 2020-05-01
EA202090119A1 (ru) 2020-04-21
US20200115342A1 (en) 2020-04-16
WO2019006283A1 (en) 2019-01-03
KR102630575B1 (ko) 2024-01-29
MX2021015656A (es) 2022-02-03
BR112019027259A2 (pt) 2020-07-14
JP7690284B2 (ja) 2025-06-10
IL271601A (en) 2020-02-27
US20220169615A1 (en) 2022-06-02
JP2020526520A (ja) 2020-08-31
EP3644993B1 (en) 2023-08-02
AU2018294314B2 (en) 2024-09-19
CN111093651B (zh) 2023-06-06
EP3644993A4 (en) 2021-03-10
EP3644993A1 (en) 2020-05-06
MX2019014885A (es) 2020-02-13
US12421195B2 (en) 2025-09-23
AU2018294314A1 (en) 2020-02-06
KR20200020916A (ko) 2020-02-26
MX391848B (es) 2025-03-19
US11236049B2 (en) 2022-02-01

Similar Documents

Publication Publication Date Title
IL271601A (en) Amorphous and crystalline forms of IDO inhibitors
IL282552A (en) Crystalline forms of MNK inhibitors
IL261606A (en) Inhibitors of transfected menin-mll and methods of use
IL267291A (en) Actonucleotidase inhibitors and methods of using them
IL274504A (en) 2ACSS inhibitors and methods of their use
IL259801A (en) ezh2 inhibitors and methods of using them
HUE062460T2 (hu) TRPC6 inhibitorok
ZA201904460B (en) Inhibitors of nhe-mediated antiport
ZA201906464B (en) Crystalline forms of (s)-afoxolaner
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
HUE066360T2 (hu) Eravaciklin kristályformái
PL3532457T3 (pl) Postacie krystaliczne hydroksynorketaminy
IL251197A0 (en) The crystal forms of tyrosine kinase inhibitors and their salts
IL270961A (en) Crystalline form of N-butyldeoxygalactonogirimycin
IL269073A (en) Crystalline forms of obeticholic acid
PL3327012T3 (pl) Krystaliczne postacie bilastyny i sposoby ich wytwarzania
IL273604A (en) New compounds and their use as selective inhibitors of caspase-2
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
SMT202000258T1 (it) Forma cristallina di inibitore del recettore degli androgeni e procedimento di preparazione dello stesso
IL277866A (en) Aminothiazoles were substituted as nuclease inhibitors
IL274758A (en) Crystalline forms of praquinostat
IL270937A (en) Crystalline forms of saltalicib
GB201612717D0 (en) Amorphous and crystaline forms of tadalfil
IL252162A0 (en) Crystal forms of poly(adenosine diphosphate) ribose polymerase inhibitors
EP3381922A4 (en) Crystals of thiadiazole derivative dpp-iv inhibitors and uses thereof